Conference
A phase II study of durvalumab re-treatment plus /- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A)
Authors
Ellis PM; Taylor SK; Bradbury PA; Goffin JR; Juergens RA; Laurie SA; Liu G; Spratlin JL; Chau NG; Charpentier D
Volume
41
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Publication Date
June 1, 2023
Name of conference
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference place
IL, Chicago
Conference start date
June 2, 2023
Conference end date
June 6, 2023
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
16
ISSN
0732-183X